Corixa Corp

Sanaria Inc. is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. The firm s vaccine development efforts are focused on African children, the population most urgently in need of protection. Based in Rockville, Md., it houses a custom-designed and constructed dedicated clinical manufacturing facility for producing its attenuated malaria parasite vaccine. Sanaria Inc. has two ongoing Cooperative Research and Development Agreements (CRADAs) with U.S. government laboratories, a development contract with a biotechnology company, a funded research agreement with a nonprofit, and a services agreement with a nonprofit research institute and a government laboratory.

Advanced BioScience Laboratories began as Bionetics Research Laboratories, which was established in 1961 to conduct biomedical contract research. In 1968, Bionetics was acquired by Litton Industries and became Litton Bionetics. The company was awarded the initial National Cancer Institute (NCI) contract in 1972 to convert what was then the Fort Detrick Biological Warfare Facilities into what became the NCI-Frederick Cancer Research and Development Center, and to establish the technical and scientific programs at the site. Advanced BioScience Laboratories is a wholly owned subsidiary of bioM rieux.

MaxCyte, Inc., based in Rockville, MD, empowers scientists in cell therapy, protein production, and cell-based assay development through its advanced Flow Electroporation technology and SeQure DX services, facilitating efficient and precise cell engineering. With over 25 years of experience, the company adopts a partnership-first approach, enabling customers to advance from discovery to commercialization with confidence. Through its innovative ExPERT platform, MaxCyte offers high-efficiency non-viral transfection solutions that cater to a diverse range of applications, including gene editing and vaccine development. The company prioritizes customer support, providing expert guidance and flexible licensing models that aim to accelerate development while mitigating risks for therapy developers. Generated from the website